| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285
Correspondence: Address all correspondence and requests for reprints to: Sunil Nagpal, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285. E-mail: nagpal_sunil{at}lilly.com
1
,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], the active metabolite of vitamin D3, is known for the maintenance of mineral homeostasis and normal skeletal architecture. However, apart from these traditional calcium-related actions, 1,25-(OH)2D3 and its synthetic analogs are being increasingly recognized for their potent antiproliferative, prodifferentiative, and immunomodulatory activities. These actions of 1,25-(OH)2D3 are mediated through vitamin D receptor (VDR), which belongs to the superfamily of steroid/thyroid hormone nuclear receptors. Physiological and pharmacological actions of 1,25-(OH)2D3 in various systems, along with the detection of VDR in target cells, have indicated potential therapeutic applications of VDR ligands in inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, actinic keratosis, seborrheic dermatitis, photoaging), osteoporosis (postmenopausal and steroid-induced osteoporosis), cancers (prostate, colon, breast, myelodysplasia, leukemia, head and neck squamous cell carcinoma, and basal cell carcinoma), secondary hyperparathyroidism, and autoimmune diseases (systemic lupus erythematosus, type I diabetes, multiple sclerosis, and organ transplantation). As a result, VDR ligands have been developed for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. Furthermore, encouraging results have been obtained with VDR ligands in clinical trials of prostate cancer and hepatocellular carcinoma. This review deals with the molecular aspects of noncalcemic actions of vitamin D analogs that account for the efficacy of VDR ligands in the above-mentioned indications.
This article has been cited by other articles:
 |
|
 |
|
  P. Alborzi, N. A. Patel, C. Peterson, J. E. Bills, D. M. Bekele, Z. Bunaye, R. P. Light, and R. Agarwal Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial Hypertension, August 1, 2008; 52(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sanchez-Martinez, A. Zambrano, A. I. Castillo, and A. Aranda Vitamin D-Dependent Recruitment of Corepressors to Vitamin D/Retinoid X Receptor Heterodimers Mol. Cell. Biol., June 1, 2008; 28(11): 3817 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F Holick and T. C Chen Vitamin D deficiency: a worldwide problem with health consequences Am. J. Clinical Nutrition, April 1, 2008; 87(4): 1080S - 1086S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ishizawa, M. Matsunawa, R. Adachi, S. Uno, K. Ikeda, H. Masuno, M. Shimizu, K.-i. Iwasaki, S. Yamada, and M. Makishima Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia J. Lipid Res., April 1, 2008; 49(4): 763 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. McCann and B. N. Ames Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J, April 1, 2008; 22(4): 982 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Bushinsky and P. Messa Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients NDT Plus, January 1, 2008; 1(suppl_1): i18 - i23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J B. Richards, A. M Valdes, J. P Gardner, D. Paximadas, M. Kimura, A. Nessa, X. Lu, G. L Surdulescu, R. Swaminathan, T. D Spector, et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1420 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ehrchen, L. Helming, G. Varga, B. Pasche, K. Loser, M. Gunzer, C. Sunderkotter, C. Sorg, J. Roth, and A. Lengeling Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major FASEB J, October 1, 2007; 21(12): 3208 - 3218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Holick Vitamin D Deficiency N. Engl. J. Med., July 19, 2007; 357(3): 266 - 281. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Seoane, I. Ben, V. Centeno, and R. Perez-Fernandez Cellular Expression Levels of the Vitamin D Receptor Are Critical to Its Transcriptional Regulation by the Pituitary Transcription Factor Pit-1 Mol. Endocrinol., July 1, 2007; 21(7): 1513 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Albert, E. A. Scheef, S. Wang, F. Mehraein, S. R. Darjatmoko, C. M. Sorenson, and N. Sheibani Calcitriol Is a Potent Inhibitor of Retinal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2327 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Inaba, K. Yamamoto, N. Yoshimoto, M. Matsunawa, S. Uno, S. Yamada, and M. Makishima Vitamin D3 Derivatives with Adamantane or Lactone Ring Side Chains are Cell Type-Selective Vitamin D Receptor Modulators Mol. Pharmacol., May 1, 2007; 71(5): 1298 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Compher, M. Pazianas, S. Benedict, J. C. Brown, B. P. Kinosian, and M. Hise Systemic Inflammatory Mediators and Bone Homeostasis in Intestinal Failure JPEN J Parenter Enteral Nutr, March 1, 2007; 31(2): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. London, A. P. Guerin, F. H. Verbeke, B. Pannier, P. Boutouyrie, S. J. Marchais, and F. Metivier Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency J. Am. Soc. Nephrol., February 1, 2007; 18(2): 613 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Penna, S. Amuchastegui, C. Cossetti, F. Aquilano, R. Mariani, F. Sanvito, C. Doglioni, and L. Adorini Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol J. Immunol., December 15, 2006; 177(12): 8504 - 8511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Moore, S. Kato, W. Xie, D. J. Mangelsdorf, D. R. Schmidt, R. Xiao, and S. A. Kliewer International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor Pharmacol. Rev., December 1, 2006; 58(4): 742 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Castillo, R. Sanchez-Martinez, A. M. Jimenez-Lara, A. Steinmeyer, U. Zugel, and A. Aranda Characterization of Vitamin D Receptor Ligands with Cell-Specific and Dissociated Activity Mol. Endocrinol., December 1, 2006; 20(12): 3093 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Banach-Petrosky, X. Ouyang, H. Gao, K. Nader, Y. Ji, N. Suh, R. S. DiPaola, and C. Abate-Shen Vitamin d inhibits the formation of prostatic intraepithelial neoplasia in nkx3.1; pten mutant mice. Clin. Cancer Res., October 1, 2006; 12(19): 5895 - 5901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, M. Yamazaki, L. A. Zella, N. K. Shevde, and J. W. Pike Activation of Receptor Activator of NF-{kappa}B Ligand Gene Expression by 1,25-Dihydroxyvitamin D3 Is Mediated through Multiple Long-Range Enhancers. Mol. Cell. Biol., September 1, 2006; 26(17): 6469 - 6486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sun, J. Kong, Y. Duan, F. L. Szeto, A. Liao, J. L. Madara, and Y. C. Li Increased NF-{kappa}B activity in fibroblasts lacking the vitamin D receptor Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E315 - E322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nonn, L. Peng, D. Feldman, and D. M. Peehl Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D. Cancer Res., April 15, 2006; 66(8): 4516 - 4524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Wright Make No Bones About It: Increasing Epidemiologic Evidence Links Vitamin D to Pulmonary Function and COPD Chest, December 1, 2005; 128(6): 3781 - 3783. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
